Technical Analysis for GLTO - Galecto, Inc.

Grade Last Price % Change Price Change
B 2.24 0.00% 0.00
GLTO closed up 1.82 percent on Monday, January 30, 2023, on 51 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Feb 15
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Wide Bands Range Expansion 1.82%
Overbought Stochastic Strength 1.82%
Outside Day Range Expansion 9.27%
Wide Bands Range Expansion 9.27%
Overbought Stochastic Strength 9.27%
Gapped Down Weakness 9.27%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% 24 minutes ago
Down 3% 24 minutes ago
Fell Below Previous Day's Low 24 minutes ago
Down 2 % 24 minutes ago
Down 1% 24 minutes ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Galecto, Inc. Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Non Alcoholic Fatty Liver Disease Breakthrough Therapy Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Progressive Fibrosis mTOR Fibrotic Disease Myelofibrosis Copenhagen Lectins Lung Diseases Treatment Of Fibrosis Galectin Galectin 3 Galecto Biotech Primary Myelofibrosis

Is GLTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.8
52 Week Low 1.04
Average Volume 57,414
200-Day Moving Average 1.81
50-Day Moving Average 1.58
20-Day Moving Average 1.83
10-Day Moving Average 2.01
Average True Range 0.18
RSI 67.85
ADX 18.84
+DI 29.53
-DI 16.46
Chandelier Exit (Long, 3 ATRs) 1.74
Chandelier Exit (Short, 3 ATRs) 1.59
Upper Bollinger Bands 2.43
Lower Bollinger Band 1.22
Percent B (%b) 0.84
BandWidth 66.12
MACD Line 0.18
MACD Signal Line 0.14
MACD Histogram 0.0363
Fundamentals Value
Market Cap 55.07 Million
Num Shares 24.6 Million
EPS
Price-to-Sales 0.00
Price-to-Book 11.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.39
Resistance 3 (R3) 2.38 2.33 2.37
Resistance 2 (R2) 2.33 2.29 2.33 2.36
Resistance 1 (R1) 2.28 2.26 2.31 2.29 2.35
Pivot Point 2.23 2.23 2.24 2.23 2.23
Support 1 (S1) 2.18 2.19 2.21 2.19 2.13
Support 2 (S2) 2.13 2.16 2.13 2.12
Support 3 (S3) 2.08 2.13 2.12
Support 4 (S4) 2.09